Discovery of novel mechanisms and molecular targets for the inhibition of activated thrombin activatable fibrinolysis inhibitor

Journal of Thrombosis and Haemostasis

Volumn 6, Issue 11, 2008, Pages 1892-1899

  Hillmayer, K ^a   Vancraenenbroeck, R ^b   De Maeyer, M ^b   Compernolle, G ^a   Declerck, P J ^a   Gils, Ann ^a  

^a UNIVERSITY OF LEUVEN   (Belgium)

^b IRC KUL Campus Kortrijk   (Belgium)

Author keywords

Fibrinolysis; Inhibitor; Monoclonal antibodies; Rat TAFI

Indexed keywords

ARGININE; CARBOXYPEPTIDASE; ENZYME INHIBITOR; FIBRIN; MONOCLONAL ANTIBODY; MONOCLONAL ANTIBODY RT13B2; MONOCLONAL ANTIBODY RT30D8; MONOCLONAL ANTIBODY RT36A3F5; MONOCLONAL ANTIBODY RT36B2; MONOCLONAL ANTIBODY RT82F12; SERINE; THROMBIN ACTIVATABLE FIBRINOLYSIS INHIBITOR; TISSUE PLASMINOGEN ACTIVATOR; TYROSINE; UNCLASSIFIED DRUG;

ARTICLE; BLOOD CLOT LYSIS; CONTROLLED STUDY; DRUG PROTEIN BINDING; ENZYME ACTIVE SITE; EPITOPE MAPPING; FIBRINOLYSIS; HUMAN; IN VITRO STUDY; INHIBITION KINETICS; MEDICAL RESEARCH; NONHUMAN; POTATO; PRIORITY JOURNAL; PROTEIN INTERACTION; PROTEIN TARGETING; RAT;

AMINO ACIDS; ANIMALS; ANTIBODIES, MONOCLONAL; ANTIFIBRINOLYTIC AGENTS; CARBOXYPEPTIDASE U; DRUG DELIVERY SYSTEMS; EPITOPE MAPPING; EPITOPES; FIBRINOLYSIS; RATS; TISSUE PLASMINOGEN ACTIVATOR;

EID: 54149105360     PISSN: 15387933     EISSN: 15387836     Source Type: Journal    
DOI: 10.1111/j.1538-7836.2008.03130.x     Document Type: Article

References (35)

1. Hendriks D, Wang W, Scharpe S, Lommaert MP, van-Sande M. Purification and characterization of a new arginine carboxypeptidase in human serum. Biochim Biophys Acta 1990; 1034: 86-92.
2. Eaton DL, Malloy BE, Tsai SP, Henzel W, Drayna D. Isolation, molecular cloning, and partial characterization of a novel carboxypeptidase B from human plasma. J Biol Chem 1991; 266: 21833-8.
3. Bajzar L, Manuel R, Nesheim ME. Purification and characterization of TAFI, a thrombin-activable fibrinolysis inhibitor. J Biol Chem 1995; 270: 14477-84.
4. Bajzar L, Morser J, Nesheim M. TAFI, or plasma procarboxypeptidase B, couples the coagulation and fibrinolytic cascades through the thrombin-thrombomodulin complex. J Biol Chem 1996; 271: 16603-8.
5. Tan AK, Eaton DL. Activation and characterization of procarboxypeptidase B from human plasma. Biochemistry 1995; 34: 5811-6.
6. Campbell WD, Lazoura E, Okada N, Okada H. Inactivation of C3a and C5a octapeptides by carboxypeptidase R and carboxypeptidase N. Microbiol Immunol 2002; 46: 131-4.
7. Myles T, Nishimura T, Yun TH, Nagashima M, Morser J, Patterson AJ, Pearl RG, Leung LL. Thrombin activatable fibrinolysis inhibitor, a potential regulator of vascular inflammation. J Biol Chem 2003; 278: 51059-67.
8. te Velde EA, Wagenaar GTM, Reijerkerk A, Roose-Girma M, Borel Rinkes HM, Voest EE, Bouma BN, Gebbink MFBG, Meijers JCM. Impaired healing of cutaneous wounds and colonic anastomoses in mice lacking thrombin-activatable fibrinolysis inhibitor. J Thromb Haemost 2003; 1: 2087-96.
9. Asai S, Sato T, Tada T, Miyamoto T, Kimbara N, Motoyama N, Okada H, Okada N. Absence of procarboxypeptidase R induces complement-mediated lethal inflammation in lipopolysaccharide-primed mice. J Immunol 2004; 173: 4669-74.
10. Boffa MB, Koschinsky ML. Curiouser and curiouser: Recent advances in measurement of thrombin-activatable fibrinolysis inhibitor (TAFI) and in understanding its molecular genetics, gene regulation, and biological roles. Clin Biochem 2007; 40: 431-42.
11. Boffa MB, Bell R, Stevens WK, Nesheim ME. Roles of thermal instability and proteolytic cleavage in regulation of activated thrombin-activable fibrinolysis inhibitor. J Biol Chem 2000; 275: 12868-78.
12. Marx PF, Hackeng TM, Dawson PE, Griffin JH, Meijers JC, Bouma BN. Inactivation of active thrombin-activable fibrinolysis inhibitor takes place by a process that involves conformational instability rather than proteolytic cleavage. J Biol Chem 2000; 275: 12410-5.
13. Hillmayer K, Macovei A, Pauwels D, Compernolle G, Declerck PJ, Gils A. Characterization of rat thrombin-activatable fibrinolysis inhibitor (TAFI) - a comparative study assessing the biological equivalence of rat, murine and human TAFI. J Thromb Haemost 2006; 4: 2470-7.
14. Schneider M, Boffa MB, Stewart R, Rahman M, Koschinsky M, Nesheim M. Two naturally occurring variants of TAFI (Thr-325 and Ile-325) differ substantially with respect to thermal stability and antifibrinolytic activity of the enzyme. J Biol Chem 2002; 277: 1021-30.
15. Boffa MB, Wang W, Bajzar L, Nesheim ME. Plasma and recombinant thrombin-activable fibrinolysis inhibitor (TAFI) and activated TAFI compared with respect to glycosylation, thrombin/ thrombomodulin-dependent activation, thermal stability, and enzymatic properties. J Biol Chem 1998; 273: 2127-35.
16. Polla MO, Tottie L, Norden C, Linschoten M, Musil D, Trumpp-Kallmeyer S, Aukrust IR, Ringom R, Holm KH, Neset SM, Sandberg M, Thurmond J, Yu P, Hategan G, Anderson H. Design and synthesis of potent, orally active, inhibitors of carboxypeptidase U (TAFIa). Bioorg Med Chem 2004; 12: 1151-75.
17. Zirlik A. TAFI: A promising drug target? Thromb Haemost 2004; 91: 420-2.
18. Do YH, Gifford-Moore DS, Beight DW, Rathnachalam R, Klimkowski VJ, Warshawsky AM, Lu D. Inhibition of thrombin activatable fibrinolysis inhibitor by cysteine derivatives. Thromb Res 2005; 116: 265-71.
19. Leurs J, Hendriks D. Carboxypeptidase U (TAFIa): A metallocarboxypeptidase with a distinct role in haemostasis and a possible risk factor for thrombotic disease. Thromb Haemost 2005; 94: 471-87.
20. Rawlings ND, Morton FR, Barrett AJ. MEROPS: The peptidase database. Nucleic Acids Res 2006; 34: D270-2.
21. Vendrell J, Querol E, Aviles FX. Metallocarboxypeptidases and their protein inhibitors. Structure, function and biomedical properties. Biochim Biophys Acta 2000; 1477: 284-98.
22. Walker JB, Hughes B, James I, Haddock P, Kluft C, Bajzar L. Stabilization versus inhibition of TAFIa by competitive inhibitors in vitro. J Biol Chem 2003; 278: 8913-21.
23. Schneider M, Nesheim M. Reversible inhibitors of TAFIa can both promote and inhibit fibrinolysis. J Thromb Haemost 2003; 1: 147-54.
24. Gils A, Ceresa E, Macovei AM, Marx PF, Peeters M, Compernolle G, Declerck PJ. Modulation of TAFI function through different pathways: implications for the development of TAFI inhibitors. J Thromb Haemost 2005; 3: 2745-53.
25. Binette TM, Taylor FB Jr, Peer G, Bajzar L. Thrombin-thrombomodulin connects coagulation and fibrinolysis: More than an in vitro phenomenon. Blood 2007; 110: 3168-75.
26. Hillmayer K, Brouwers E, Leon-Tamariz F, Meijers JC, Marx PF, Declerck PJ, Gils A. Development of sandwich-type ELISAs for the quantification of rat and murine thrombin activatable fibrinolysis inhibitor in plasma. J Thromb Haemost 2008; 6: 132-8.
27. Mutch NJ, Thomas L, Moore NR, Lisiak KM, Booth NA. TAFIa, PAI-1 and alpha-antiplasmin: Complementary roles in regulating lysis of thrombi and plasma clots. J Thromb Haemost 2007; 5: 812-7.
28. Fiser A, Sali A. Modeller: Generation and refinement of homology-based protein structure models. Methods Enzymol 2003; 374: 461-91.
29. De Maeyer M, Desmet J, Lasters I. The dead-end elimination theorem: mathematical aspects, implementation, optimizations, evaluation, and performance. Methods Mol Biol 2000; 143: 265-304.
30. van der Spoel D, Lindahl E, Hess B, Groenhof G, Mark AE, Berendsen HJ. GROMACS: Fast, flexible, and free. J Comput Chem 2005; 26: 1701-18.
31. Ceresa E, De Maeyer M, Jonckheer A, Peeters M, Engelborghs Y, Declerck PJ, Gils A. Comparative evaluation of stable TAFIa variants: Importance of alpha-helix 9 and beta-sheet 11 for TAFIa (in)stability. J Thromb Haemost 2007; 5: 2105-12.
32. Delhaise P, Bardiaux M, De Maeyer M, Prevost M, Vanbelle D, Donneux J, Lasters I, Vancutsem E, Alard P, Wodak SJ. The Brugel Package-Toward computer-aided-design of macromolecules. J Mol Graph 1988; 6: 219.
33. DeLano WL. The PyMOL Molecular Graphics System on World Wide Web. http://pymol.sourceforge.net; accessed 2 September 2008.
34. Wang YX, Zhao L, Nagashima M, Vincelette J, Sukovich D, Li W, Subramanyam B, Yuan S, Emayan K, Islam I, Hrvatin P, Bryant J, Light DR, Vergona R, Morser J, Buckman BO. A novel inhibitor of activated thrombin-activatable fibrinolysis inhibitor (TAFIa) - part I: pharmacological characterization. Thromb Haemost 2007; 97: 45-53.
35. Islam I, Bryant J, May K, Mohan R, Yuan S, Kent L, Morser J, Zhao L, Vergona R, White K, Adler M, Whitlow M, Buckman BO. 3-Mercaptopropionic acids as efficacious inhibitors of activated thrombin activatable fibrinolysis inhibitor (TAFIa). Bioorg Med Chem Lett 2007; 17: 1349-54.